Kanoia: The first dose in the CMG901 Phase III clinical trial has been administered, and received a $45 million milestone payment from AstraZeneca

LightningPacketLoss · 2026-03-11T22:05:46+00:00

Kanoya and AstraZeneca have updated their collaboration. Their core product, CMG901, has initiated Phase III clinical trials targeting Claudin18.2-positive advanced gastric cancer. This study triggered a milestone payment of $45 million. CMG901 has received clinical approval in China and the US and is regarded as an anti-cancer targeted drug.

LightningPacketLoss

2026-03-11 22:05:46

Abstract generation in progress

Recently, Conoya announced an update on its collaboration with AstraZeneca regarding the core product CMG901 (AZD0901). In February 2023, the company’s wholly-owned subsidiary KYM signed a global exclusive licensing agreement with AstraZeneca to develop and commercialize CMG901.

According to the announcement, AstraZeneca has initiated a Phase III clinical trial aimed at treating advanced/metastatic gastric cancer positive for Claudin18.2 and negative for HER2. The first patient in this trial has completed dosing. The start of this clinical trial triggered milestone payments totaling $45 million, of which the company has received payment from AstraZeneca (net of bank fees).

CMG901 is an antibody-drug conjugate targeting Claudin18.2, which has received clinical trial application approval in China and the United States. The drug is considered an ideal target for treating gastric cancer, pancreatic cancer, and other solid tumors, and was granted breakthrough therapy designation in September 2022.

(Conoya Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.